Issue link: https://nebusinessmedia.uberflip.com/i/1513532
wbjournal.com | December 25, 2023 | Worcester Business Journal 29 Member FDIC Member DIF WE HELP KEEP YOUR BUSINESS GROWING. Call one of our experienced commercial lenders at 800-649-3036 or email us at commercial@saversbank.com. Simply Beter. Commercial Loans, Business Banking and So Much More. saversbank.com/ businessbanking Warehouse Storage For Rent Asset Management Program Office and Lab Moving WE KNOW STORAGE!!!! thestoragecompany.com "It is reasonably foreseeable that addi- tional layoffs may occur within the next ninety (90) days," David LaChappelle, director of employee and labor relations for UMass Chan wrote in a letter accom- panying the WARN notice. MassBiologics is a nonprofit vaccine manufacturer producing tetanus-diph- theria vaccines. MassBiologics has 120 employees. ere will be 84 employees aer the layoffs are completed in February. e eliminated positions are across a number of job functions, according to the letter. Eight eliminations are of manufacturing associates. Employees impacted will receive severance and outplacement service assistance, according to a statement sent to WBJ on Dec. 11. e decision is a result of impacts on the local, regional and nationwide life sciences and vaccine manufacturing sectors. e layoffs are intended to right- size operations. "While a reduction in our workforce is always regrettable and a last resort, MassBiologics is not immune from mar- ket-related factors impacting so many biotech and life sciences companies at this time which include, but are not limited to, high overhead, underutilized biomanufacturing capacity and, in this case, steadily waning demand for Td [tet- anus-diphtheria] vaccine," Sarah Willey, media relations manager at UMass Chan, said in a Dec. 11 statement sent to the Worcester Business Journal. In March, the medical school eliminat- ed 26 positions at MassBiologics. In No- vember, UMass Chan announced 70 jobs would be eliminated from its purview as a contract expired. Mustang Bio sells Worcester facility for $11M, to transfer manufacturing operations Biopharmaceutical company Mus- tang Bio has sold its 27,000-square-foot development, manufacturing, and testing facility in Worcester to a Boston firm specializing in cell-and-gene therapy for $11 million. at firm, uBriGene Biosci- ences, will take over the manufacturing of Mustang Bio's lead product candidates Continued on next page